By analyzing tumor-infiltrating immune cells, we found that LC treatment markedly increased the proportion of CD8+ T cells but did not alter the proportion of CD4+ regulatory T cells, CD11b+ myeloid cells and B cells in B16, MC38 and 4T1 tumor models (Extended Data Fig. 7e). The gene discussed is CD8A; the disease is neoplasm.